“The Italian Society of Gerontology and Geriatrics” Sigg “dealt with Herpes zoster starting from a cognitive assessment of the attitude of Italian geriatricians with respect to vaccination in general and with respect to vaccination for Herpes zoster. Through a survey developed last year , we realized that there is still little sensitivity regarding the Herpes zoster vaccination. For this reason a group of researchers, representative of all Italy, has set to work and has reviewed the guidelines, and those that are the scientific evidence regarding herpes zoster vaccination Objective: to create a position paper that is now visible on the Sigg website (www.sigg.it) and in which you can find all the specific information on the severity of the disease, its consequences, such as peripheral neuropathy, and complications not related to peripheral neuropathy, and obviously vaccination possibilities “. Thus at Adnkrons Health Francesco Landi, president Sigg, on the sidelines of the conference ‘Strategies and tools to increase vaccination prevention against Herpes zoster’, which was held today at the Ministry of Health.
“Today the advantage of having a recombinant vaccine adjuvanted with two successive administrations – underlines Landi – lies in the scientific evidence that substantially shows that efficacy reaches over 90%. This means that almost total protection is obtained compared to Herpes zoster. in people under 50 and in people over 70 years of age. Another interesting aspect is that even in subjects who, despite the vaccine, develop the reactivation of the Varicella zoster virus (Vzv) in fact complications, in particular neuropathy peripheral and post-herpetic diseases, and complications not related to peripheral neuropathy, are substantially absent. So even where the vaccine fails to fully protect against the disease, complications are in fact irrelevant. Adverse reactions? Pain at the injection site and a little tiredness and myalgia for a few days “.